# US 9,750,852 B2 · Modification of bioabsorbable stent to reduce thrombogenecity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,750,852 B2
- Document ID: US9750852B2
- Status: Granted
- Kind: B2
- Application number: 15/188,698
- Filed: 2016-06-21
- Published: 2016-10-13
- Granted: 2017-09-05
- Earliest claimed: 2011-05-10
- Assignees: Abbott Cardiovascular Systems Inc.
- Applicants: Abbott Cardiovascular Systems Inc.
- Inventors: Derek Mortisen; Yunbing Wang
- Web page: https://patentgrep.com/patent/US9750852B2

## CPC

- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61F 2/915: with bands having a meander structure, adjacent bands being connected to each other
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61L 31/10: Macromolecular materials
- A61L 31/148: {Materials at least partially resorbable by the body}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61F 2002/91575: {connected peak to trough}
- A61F 2002/91583: {by a bridge, whereby at least one of its ends is connected along the length of a strut between two consecutive apices within a band}
- A61F 2210/0004: bioabsorbable
- A61F 2230/0054: V-shaped
- A61F 2230/0056: W-shaped, e.g. M-shaped, sigma-shaped
- A61F 2250/0067: Means for introducing or releasing pharmaceutical products into the body
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/42: Anti-thrombotic agents, anticoagulants, anti-platelet agents
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Bioabsorbable polymer scaffolds with coatings are disclosed that include immobilized antithrombotic agents on the scaffolds or in or on the coatings. The agents act synergistically with antiproliferative agents released from coatings by providing hemocompatibility during and without interfering with antiproliferative agent release. Methods of modifying scaffolds and coatings with the antithrombotic agents are disclosed.

## Claims

### Claim 1

A bioabsorbable stent comprising:
a poly(L-lactide) (PLLA) scaffolding composed of a plurality of struts having a thickness between 100 and 200 microns and;
a first coating layer above all or a portion of the PLLA scaffolding having a thickness less than 5 microns,
wherein the coating layer comprises an antiproliferative drug distributed throughout a coating polymer,
wherein immobilized antithrombotic agent is at an outer surface of the coating layer,
wherein the coating layer is free of the immobilized antithrombotic agent below the outer surface of the coating layer,
wherein the antithrombotic agent is selected from the group consisting of heparin, non-adhesive proteins, cell adhesive proteins, cell adhesive peptide sequences, and hydrophilic monomers or polymers.

### Claim 2 (depends on 1)

The stent of claim 1, wherein the coating polymer is selected from the group consisting of poly(DL-lactide) (PDLLA) and poly(L-lactide-co-glycolide) (PLGA).

### Claim 3 (depends on 1)

The stent of claim 1, wherein the coating polymer is selected from the group consisting of hydrophobic aliphatic polyanhydrides, hydrophobic aromatic polyanhydrides, polyester amides, poly(ortho esters), and polyketals.

### Claim 4 (depends on 1)

The stent of claim 1, wherein the hydrophilic monomers or polymers are selected from the group consisting of 2-hydroxyethylmethacrylate (HEMA), polyethylene glycol methyl ether acrylate (mPEG-acrylate), phosphorylcholine methacrylate, hydroxypropylmethacrylate (HPMA), and methacrylic acid.

### Claim 5 (depends on 1)

The stent of claim 1, wherein the heparin is immobilized to the coating polymer with amide linkages.

### Claim 6 (depends on 1)

The stent of claim 1, wherein the heparin is immobilized to the coating polymer through bonding between amino groups of the heparin to carboxylic groups of the coating polymer.

### Claim 7 (depends on 1)

The stent of claim 1, wherein the heparin is immobilized to the coating polymer through bonding between carboxylic groups of the heparin to amino groups of the coating polymer.